NASDAQ:VCNXVaccinex Stock Price, Forecast & News

Vaccinex's stock was trading at $4.17 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, VCNX stock has increased by 3.6% and is now trading at $4.32. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaccinex in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Vaccinex.

Vaccinex is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Vaccinex.

Vaccinex Inc (NASDAQ:VCNX) posted its quarterly earnings data on Thursday, May, 14th. The company reported ($0.45) EPS for the quarter, topping analysts' consensus estimates of ($0.75) by $0.30. View Vaccinex's earnings history.

1 brokerages have issued 1 year target prices for Vaccinex's shares. Their forecasts range from $22.00 to $22.00. On average, they anticipate Vaccinex's stock price to reach $22.00 in the next year. This suggests a possible upside of 409.3% from the stock's current price. View analysts' price targets for Vaccinex.

Media headlines about VCNX stock have trended somewhat negative on Thursday, according to InfoTrie. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Vaccinex earned a coverage optimism score of -1.6 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View the latest news about Vaccinex.

Some companies that are related to Vaccinex include CymaBay Therapeutics (CBAY), Selecta Biosciences (SELB), Agile Therapeutics (AGRX), Fortress Biotech (FBIO), Hookipa Pharma (HOOK), Five Prime Therapeutics (FPRX), Paratek Pharmaceuticals (PRTK), Marinus Pharmaceuticals (MRNS), Aptinyx (APTX), Kalvista Pharmaceuticals (KALV), Aduro BioTech (ADRO), OptiNose (OPTN), Strongbridge Biopharma (SBBP), Lexicon Pharmaceuticals (LXRX) and XOMA (XOMA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaccinex investors own include Agile Therapeutics (AGRX), Aduro BioTech (ADRO), Crispr Therapeutics (CRSP), Exelixis (EXEL), VBI Vaccines (VBIV), vTv Therapeutics (VTVT), Opko Health (OPK), SCYNEXIS (SCYX), Sangamo Therapeutics (SGMO) and Whiting Petroleum (WLL).

(VCNX) raised $45 million in an initial public offering (IPO) on Thursday, August 9th 2018. The company issued 3,300,000 shares at a price of $12.00-$15.00 per share. Oppenheimer and BTIG acted as the underwriters for the IPO and Ladenburg Thalmann was co-manager.

Vaccinex trades on the NASDAQ under the ticker symbol "VCNX."

Shares of VCNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VCNX stock can currently be purchased for approximately $4.32.

Vaccinex has a market capitalization of $71.91 million and generates $520,000.00 in revenue each year. The company earns $-31,860,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis. Vaccinex employs 44 workers across the globe.

The official website for Vaccinex is www.vaccinex.com.

Vaccinex's mailing address is 1895 MOUNT HOPE AVENUE, ROCHESTER NY, 14620. The company can be reached via phone at 585-271-2700 or via email at [email protected]